.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Colorcon
Fish and Richardson
Moodys
US Department of Justice
Boehringer Ingelheim
Chinese Patent Office
Teva
Mallinckrodt
Queensland Health

Generated: December 15, 2017

DrugPatentWatch Database Preview

INDERAL LA Drug Profile

« Back to Dashboard

Which patents cover Inderal La, and what generic alternatives are available?

Inderal La is a drug marketed by Ani Pharms Inc and is included in one NDA.

The generic ingredient in INDERAL LA is propranolol hydrochloride. There are twenty-one drug master file entries for this compound. Fifty-six suppliers are listed for this compound. Additional details are available on the propranolol hydrochloride profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Ani Pharms IncINDERAL LApropranolol hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL018553-004Mar 18, 1987ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Ani Pharms IncINDERAL LApropranolol hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL018553-001Apr 19, 1983ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Ani Pharms IncINDERAL LApropranolol hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL018553-002Apr 19, 1983ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Ani Pharms IncINDERAL LApropranolol hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL018553-003Apr 19, 1983ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: INDERAL LA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ani Pharms IncINDERAL LApropranolol hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL018553-004Mar 18, 1987► Subscribe► Subscribe
Ani Pharms IncINDERAL LApropranolol hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL018553-001Apr 19, 1983► Subscribe► Subscribe
Ani Pharms IncINDERAL LApropranolol hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL018553-003Apr 19, 1983► Subscribe► Subscribe
Ani Pharms IncINDERAL LApropranolol hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL018553-002Apr 19, 1983► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Cipla
Julphar
Covington
AstraZeneca
Harvard Business School
Fuji
Chubb
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot